FDA Approves Lilly Rescue Treatment for Diabetics

Lilly plans to present trial results at scientific meetings and publications this year and in 2016.

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Diabetics at risk for very low blood sugar will soon have a new emergency tool to counter the effects. Indianapolis-based Eli Lilly and Co. (NYSE: LLY) says the U.S. Food and Drug Administration has approved BAQSIMI Nasal Powder, which is used to treat severe hypoglycemia in adults and children with diabetes who are four years and older. 

"Severe hypoglycemia is an unpredictable event for people with diabetes that can happen anytime, anywhere. It’s an experience that can be very stressful and difficult for those helping a person in a low blood sugar emergency," said Dr. Sherry Martin, Vice President of Lilly Medical Affairs.

Lilly says the treatment comes in a compact, portable and ready to use dose. It’s a dry spray form that gets absorbed through the nose.

The company says BAQSIMI is the first and only nasally administered glucagon. Lilly says some diabetes patients may have allergic reactions or hypersensitivity to glucagon, so they should first check with their physician.

Lilly expects to have the new rescue treatment in retail pharmacies within one month.